Elicio Therapeutics
ELTX
18 hedge funds and large institutions have $3.08M invested in Elicio Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
11% more capital invested
Capital invested by funds: $2.78M → $3.08M (+$303K)
0.87% more ownership
Funds ownership: 3.96% → 4.83% (+0.87%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$204K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$125K |
| 3 |
State Street
Boston,
Massachusetts
|
+$88.2K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$35.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$117K |
| 2 |
Renaissance Technologies
New York
|
-$23.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17.1K |
| 4 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
-$1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
ELTX Hedge Fund Activity: Q1 2024 in Review
18 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Elicio Therapeutics (ELTX) for Q1 2024, worth a combined $3.08M — up 11% from $2.78M a quarter earlier.
Fund positioning in ELTX was balanced in Q1 2024: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $204K. The largest seller was Citadel Advisors, exiting entirely with an estimated $117K sold.
- 18 institutional investors held Elicio Therapeutics (ELTX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $3.08M of Elicio Therapeutics stock for Q1 2024, up 11% quarter-over-quarter.
- 4 funds opened new Elicio Therapeutics positions in Q1 2024 and 4 closed out, a net change of 0 holders.
- The largest Elicio Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $204K added.
- The largest Elicio Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $117K sold.
Based on aggregated 13F filings for Q1 2024.